Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GnRH Antagonist for Early OHSS
NCT01268761Phase 3Completed
- Sponsor
- IVI
- Start
- Apr 2012
- Primary completion
- Jul 2013
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of cetrorelix in ovarian hyperstimulation syndrome (OHSS), sponsored by IVI. Started Apr 2012; status: completed.
02
Drugs
cetrorelix
03
Conditions
ovarian hyperstimulation syndrome (OHSS)
Beyond the preview
Go deeper on NCT01268761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01268761.